These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
56 related articles for article (PubMed ID: 10352478)
1. Meningioma: the impact of new techniques for the diagnosis and prognosis. Scarpelli M; Mazzucchelli R; Colanzi P Adv Clin Path; 1997 Apr; 1(2):149-153. PubMed ID: 10352478 [TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment. Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521 [TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas. Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125 [TBL] [Abstract][Full Text] [Related]
4. Meningiomas: loss of heterozygosity on chromosome 10 and marker-specific correlations with grade, recurrence, and survival. Mihaila D; Jankowski M; Gutiérrez JA; Rosenblum ML; Newsham IF; Bögler O; Rempel SA; Clin Cancer Res; 2003 Oct; 9(12):4443-51. PubMed ID: 14555517 [TBL] [Abstract][Full Text] [Related]
5. De novo versus transformed atypical and anaplastic meningiomas: comparisons of clinical course, cytogenetics, cytokinetics, and outcome. Krayenbühl N; Pravdenkova S; Al-Mefty O Neurosurgery; 2007 Sep; 61(3):495-503; discussion 503-4. PubMed ID: 17881961 [TBL] [Abstract][Full Text] [Related]
6. Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone. Maillo A; Orfao A; Espinosa AB; Sayagués JM; Merino M; Sousa P; Lara M; Tabernero MD Neuro Oncol; 2007 Oct; 9(4):438-46. PubMed ID: 17704362 [TBL] [Abstract][Full Text] [Related]
7. Cytogenetic analysis of aggressive meningiomas: possible diagnostic and prognostic implications. Perry A; Jenkins RB; Dahl RJ; Moertel CA; Scheithauer BW Cancer; 1996 Jun; 77(12):2567-73. PubMed ID: 8640707 [TBL] [Abstract][Full Text] [Related]
8. Implications of prognostic markers in brain tumors. Grzybicki DM; Moore SA Clin Lab Med; 1999 Dec; 19(4):833-47. PubMed ID: 10572718 [TBL] [Abstract][Full Text] [Related]
9. Correspondence of tumor localization with tumor recurrence and cytogenetic progression in meningiomas. Ketter R; Rahnenführer J; Henn W; Kim YJ; Feiden W; Steudel WI; Zang KD; Urbschat S Neurosurgery; 2008 Jan; 62(1):61-9; discussion 69-70. PubMed ID: 18300892 [TBL] [Abstract][Full Text] [Related]
10. Comparative genomic hybridization analysis of genomic alterations in benign, atypical and anaplastic meningiomas. Arslantas A; Artan S; Oner U; Durmaz R; Müslümanoğlu H; Atasoy MA; Başaran N; Tel E Acta Neurol Belg; 2002 Jun; 102(2):53-62. PubMed ID: 12161900 [TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas. Amatya VJ; Takeshima Y; Sugiyama K; Kurisu K; Nishisaka T; Fukuhara T; Inai K Hum Pathol; 2001 Sep; 32(9):970-5. PubMed ID: 11567227 [TBL] [Abstract][Full Text] [Related]
12. [Meningiomas: new prognostic factors]. Sanz Esponera J An R Acad Nac Med (Madr); 2007; 124(2):319-32; discussion 330-2. PubMed ID: 18069599 [TBL] [Abstract][Full Text] [Related]
13. Diagnostic validity of the Ki-67 labeling index using the MIB-1 monoclonal antibody in the grading of meningiomas. Devaprasath A; Chacko G Neurol India; 2003 Sep; 51(3):336-40. PubMed ID: 14652433 [TBL] [Abstract][Full Text] [Related]
14. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas. Ozen O; Demirhan B; Altinörs N Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545 [TBL] [Abstract][Full Text] [Related]
16. Histopathological and cytogenetic findings in benign, atypical and anaplastic human meningiomas: a study of 60 tumors. Cerdá-Nicolás M; López-Ginés C; Pérez-Bacete M; Barcia-Salorio JL; Llombart-Bosch A Clin Neuropathol; 2000; 19(6):259-67. PubMed ID: 11128617 [TBL] [Abstract][Full Text] [Related]
17. Microarray-based analysis of spinal versus intracranial meningiomas: different clinical, biological, and genetic characteristics associated with distinct patterns of gene expression. Sayagués JM; Tabernero MD; Maíllo A; Trelles O; Espinosa AB; Sarasquete ME; Merino M; Rasillo A; Vera JF; Santos-Briz A; de Alava E; Garcia-Macias MC; Orfao A J Neuropathol Exp Neurol; 2006 May; 65(5):445-54. PubMed ID: 16772868 [TBL] [Abstract][Full Text] [Related]
18. Surgery for convexity meningiomas. Morokoff AP; Zauberman J; Black PM Neurosurgery; 2008 Sep; 63(3):427-33; discussion 433-4. PubMed ID: 18812953 [TBL] [Abstract][Full Text] [Related]
19. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases. Roser F; Samii M; Ostertag H; Bellinzona M Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263 [TBL] [Abstract][Full Text] [Related]
20. Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study. Pistolesi S; Boldrini L; Gisfredi S; De Ieso K; Camacci T; Caniglia M; Lupi G; Leocata P; Basolo F; Pingitore R; Parenti G; Fontanini G Neuropathol Appl Neurobiol; 2004 Apr; 30(2):118-25. PubMed ID: 15043709 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]